We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current RGRX market cap is 200.97k. The company's latest EPS is USD -0.0120 and P/E is -50.83.
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 70k | 77k | 77k | 77k | 77k |
| Operating Income | -1.32M | -1.26M | -1.29M | -1.33M | -1.4M |
| Net Income | -1.99M | -1.49M | -1.52M | -1.6M | -1.73M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 281k | 712k | 552k | 1.29M | 382k |
| Total Liabilities | 2.49M | 3.05M | 3.38M | 3.52M | 3.83M |
| Total Equity | -2.21M | -2.34M | -2.82M | -2.23M | -3.45M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -888k | -1.14M | -1.01M | -990k | -941k |
| Investing | N/A | N/A | N/A | N/A | N/A |
| Financing | 943k | 1.54M | 795k | 1.79M | N/A |
| Market Cap | 200.97k |
| Price to Earnings Ratio | -50.83 |
| Price to Sales Ratio | 1.22k |
| Price to Cash Ratio | 305 |
| Price to Book Ratio | -25.42 |
| Dividend Yield | - |
| Shares Outstanding | 143.55M |
| Average Volume (1 week) | 100 |
| Average Volume (1 Month) | 164 |
| 52 Week Change | -99.98% |
| 52 Week High | 8.80 |
| 52 Week Low | 0.0004 |
| Spread (Intraday) | 0 (0%) |
| Company Name | RegeneRX Biopharmaceuticals Inc (CE) |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.regenerx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
